BIOLIDICS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.011 SGD | -8.33% |
|
-8.33% | -21.43% |
| Apr. 12 | Biolidics Limited Announces the Redesignation of Zhu Hua from Non-Executive Non-Independent Director to Executive Director | CI |
| Apr. 12 | Singapore Shares Fall at Market Close; Biolidics Up 9% | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 53.35 | 59.41 | 79.21 | 50.44 | 11.84 | 9.207 |
| Enterprise Value (EV) 1 | 41.77 | 53.92 | 73.82 | 50.73 | 9.825 | 11.05 |
| P/E ratio | -4.44 x | -12.4 x | -16.6 x | -8.41 x | -0.72 x | -3.33 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 40.4 x | 39.4 x | 8.54 x | 21.7 x | 4.67 x | 6.76 x |
| EV / Revenue | 31.6 x | 35.8 x | 7.96 x | 21.8 x | 3.87 x | 8.12 x |
| EV / EBITDA | -12.5 x | -12.1 x | -23.3 x | -10.3 x | -1.96 x | -4.58 x |
| EV / FCF | -18.1 x | -16.7 x | -104 x | -17.7 x | 4.68 x | -2.28 x |
| FCF Yield | -5.53% | -6% | -0.96% | -5.64% | 21.4% | -43.8% |
| Price to Book | 4.25 x | 7.65 x | 9.58 x | 21.6 x | -7.02 x | -4.63 x |
| Nbr of stocks (in thousands) | 242,500 | 242,500 | 264,047 | 265,452 | 493,368 | 657,627 |
| Reference price 2 | 0.2200 | 0.2450 | 0.3000 | 0.1900 | 0.0240 | 0.0140 |
| Announcement Date | 4/12/19 | 4/7/20 | 4/14/21 | 4/12/22 | 4/12/23 | 4/11/24 |
1SGD in Million2SGD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.32 | 1.508 | 9.278 | 2.329 | 2.536 | 1.361 |
| EBITDA 1 | -3.33 | -4.449 | -3.164 | -4.937 | -5.024 | -2.413 |
| EBIT 1 | -3.721 | -4.812 | -3.86 | -5.819 | -5.889 | -2.468 |
| Operating Margin | -281.83% | -319.14% | -41.61% | -249.82% | -232.22% | -181.34% |
| Earnings before Tax (EBT) 1 | -6.252 | -4.81 | -4.684 | -6.041 | -9.85 | -2.488 |
| Net income 1 | -6.252 | -4.81 | -4.651 | -5.984 | -9.374 | -2.488 |
| Net margin | -473.53% | -318.98% | -50.13% | -256.92% | -369.64% | -182.81% |
| EPS 2 | -0.0495 | -0.0198 | -0.0181 | -0.0226 | -0.0333 | -0.004200 |
| Free Cash Flow 1 | -2.311 | -3.236 | -0.7072 | -2.86 | 2.101 | -4.838 |
| FCF margin | -175.06% | -214.6% | -7.62% | -122.78% | 82.86% | -355.48% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/12/19 | 4/7/20 | 4/14/21 | 4/12/22 | 4/12/23 | 4/11/24 |
1SGD in Million2SGD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 0.29 | - | 1.84 |
| Net Cash position 1 | 11.6 | 5.49 | 5.39 | - | 2.02 | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.0586 x | - | -0.7625 x |
| Free Cash Flow 1 | -2.31 | -3.24 | -0.71 | -2.86 | 2.1 | -4.84 |
| ROE (net income / shareholders' equity) | 111% | -47.3% | -58% | -113% | -2,911% | 135% |
| ROA (Net income/ Total Assets) | -24% | -25.3% | -17% | -24.1% | -42% | -45.6% |
| Assets 1 | 26.07 | 19.04 | 27.35 | 24.83 | 22.3 | 5.46 |
| Book Value Per Share 2 | 0.0500 | 0.0300 | 0.0300 | 0.0100 | -0 | -0 |
| Cash Flow per Share 2 | 0.0500 | 0.0200 | 0.0400 | 0.0100 | 0.0100 | 0 |
| Capex 1 | 0.06 | 0.56 | 0.32 | 0.43 | 0.03 | - |
| Capex / Sales | 4.24% | 37.25% | 3.5% | 18.39% | 1.3% | - |
| Announcement Date | 4/12/19 | 4/7/20 | 4/14/21 | 4/12/22 | 4/12/23 | 4/11/24 |
1SGD in Million2SGD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.43% | 6.56M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +1.33% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- 8YY Stock
- Financials Biolidics Limited
